Promising new selective-TKIs under investigation are NVL-330 (HEROEX-1, NCT06521554), ELVN-002 (NCT05650879), and IAM1363-01 (NCT06253871); other TKIs active both for HER2/EGFR under investigation are HS-10376 (NCT05435274) and BH-30643 (SOLARA, NCT06706076) in NSCLC; and ABT-101 (NCT05532696), YH42946 (NCT06616766), ORIC-114 (NCT05315700), and TAS2940 (NCT04982926) in all solid tumours, which also include the HER2-altered NSCLC. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.